Latest From Incyte Corp.
Emerging Company Profile: Switzerland’s iOnctura is working on PI3K-delta inhibitors and autotaxin inhibitors that have potential in solid tumors and cancer-associated fibrosis.
Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody
With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Incyte Pharmaceuticals Inc.
- Incyte Genomics Inc.
- North America
- Parent & Subsidiaries
- Incyte Corp.
- Senior Management
Hervé A Hoppenot, MD, Pres. & CEO
Christiana Stamoulis, EVP, CFO
Dashyant Dhanak , PhD, EVP, CSO
Vijay Iyengar, MD, EVP, Global Strategy & Corp. Dev.
Steven H Stein, MD, EVP, CMO
- Contact Info
Phone: (302) 498-6700
1801 Augustine Cut-Off
Wilmington, DE 19803
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.